Peptides
ARA-290 (Cibinetide)
Also called Cibinetide
ARA-290 is researched for burning, tingling and other symptoms of small-fiber neuropathy. Small human studies give it a more specific nerve-related rationale than a generic recovery peptide, but they do not establish that it repairs every type of nerve damage or relieves everyone’s pain.
Dosage & duration
A controlled dose-comparison study in sarcoidosis-associated neuropathy.
Cibinetide dose-comparison trial
Published example · product-specific- Dose
- 1, 4 or 8 mg in separate groups
- How often
- Once daily, under the skin
- How long
- 28 consecutive days
Research arms, not an escalation ladder or a universal nerve-pain regimen.
Sources: 2
A 28-day trial does not establish a long-term maintenance schedule.
Nerve symptoms
Beyond the burning and tingling
-
Relief you can feel
Less pain, tingling or numbness is a different result from a change on a nerve test.
-
A more manageable day
Sleep, walking and ordinary activities help explain whether a change is useful.
-
Improvement that lasts
Early studies do not establish a lasting benefit for every cause of neuropathy.
Who is most interested
People with persistent burning, tingling, numbness or altered sensation often want something beyond temporary symptom relief. The cause matters: the clinical work includes sarcoidosis-associated and diabetic neuropathy, not every trapped nerve or spinal injury.
What is promising
Early controlled studies found changes in neuropathic symptoms and measures of small nerve fibers. That is a research signal worth distinguishing from a vague healing claim, but a nerve-density measure is not a guarantee that pain or function improves for each person.
How long did the studies last?
Several studies treated for 28 days and followed patients afterwards. That does not establish a universal four-week cycle, a maintenance dose or how durable any benefit will be. New or worsening sensations should not automatically be labelled “nerves waking up.”
Model details: ARA-290 (Cibinetide) · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
PKARA: healthy male crossover;4 mg SC n 5, Cmax 2.0±0.7 ng/mL, Tmax 6 min, AUC148 ng·min/mL, terminal~20 min. Later clinical paper summarizes~3 ng/mL; do not silently replace the original cohort mean.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 0.3333333 hours
- Absorption half-life assumed
- 0.02464518 hours
- Reference amount for the relative scale
- 1 mg
- The faster rate is inferred to match the 0.1 h source-scoped peak time; absorption half-life 0.024645183502450502 h is a mathematical shape parameter, not separately measured.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- Source Cmax 2 ng/mL and AUC148 ng·min/mL imply an AUC/peak ratio 1.233 h; a 20 min/6 min one-compartment curve gives about 71 ng·min/mL, substantially below 148.
- Reported 2/4/6 mg SC peaks 1.6/2.0/7.4 ng/mL are not proportional across all tested amounts.
- Bioavailability and volume must not be invented.
- ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.
PKARA: healthy male crossover;4 mg SC n 5, Cmax 2.0±0.7 ng/mL, Tmax 6 min, AUC148 ng·min/mL, terminal~20 min. Later clinical paper summarizes~3 ng/mL; do not silently replace the original cohort mean.
- Niesters et al.2013, original PKARA data within the ARA290 report
Healthy males 4mgSC n 5:peak 2.0 ng/mL at 6 min,AUC148 ng·min/mL,terminal~20 min.
ara-290-relative-timing-2026-10 · version 1
Common questions
Does ARA-290 repair every damaged nerve?
No. The cited studies concern particular small-fiber neuropathy populations, not every spinal, compression or traumatic nerve problem.
Does increased tingling mean nerves are healing?
Not necessarily. A new symptom is not proof of regeneration and can need reassessment.
Sources Labels, studies and notes behind this guide
Catalog evidence: Human clinical trials. This describes the type of evidence, not a clinical review of every claim.
Summary and fact source checks: 2026-10-07. This records source checking, not medical review of the whole page.
Notes on the quick facts
- Main interest
- Burning, tingling and altered sensation.
- Human research
- Not every cause of nerve damage.
- Expected timeline
- No guaranteed day when relief begins.
- 1. ARA-290 sarcoidosis neuropathy trial
Blinded placebo-controlled study with 28 days daily subcutaneous treatment; symptom and corneal nerve-density signals in specific disease population.
- 2. EU trial results — cibinetide dose comparison
Separate 1, 4 and 8 mg daily subcutaneous groups for 28 days in sarcoidosis-associated neuropathy.
- 3. ARA-290 diabetes neuropathy trial
Small type 2 diabetes study; early signal, not proof for all neuropathy causes.
- 4. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.
PKARA: healthy male crossover;4 mg SC n 5, Cmax 2.0±0.7 ng/mL, Tmax 6 min, AUC148 ng·min/mL, terminal~20 min. Later clinical paper summarizes~3 ng/mL; do not silently replace the original cohort mean.
- 5. Niesters et al.2013, original PKARA data within the ARA290 report
Healthy males 4mgSC n 5:peak 2.0 ng/mL at 6 min,AUC148 ng·min/mL,terminal~20 min.
- 6. Cibinetide phase 2b sarcoidosis neuropathy study
64 subjects, 28 days; 4 mg group improved corneal nerve fiber area, a surrogate endpoint. Placebo-corrected pain signal did not reach conventional significance.
- 7. ARA 290 sarcoidosis pilot
Small randomized IV pilot, nonerythropoietic EPO-derived peptide; clinical signals need confirmation.
Related compounds and examples
Related compounds
BPC-157
Why people consider BPC-157 for tendon, ligament, muscle and gut recovery, plus oral versus injected forms, expected timing and practical trade-offs.
TB-500 (Thymosin Beta-4)
Why people research TB-500 for tendon, muscle and joint recovery, how reported courses are described, and what to know when comparing it with BPC-157.
TB-500 Fragment
The TB-500 fragment is a small piece of thymosin beta-4. Researchers study both the fragment and what it breaks down into; these can have different effects in laboratory experiments.